Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apotex Rumored To Be Weighing $3bn Sale

Executive Summary

The family of murdered billionaire Barry Sherman who founded Canada’s largest generic drugmaker Apotex is rumored to be weighing whether to sell the business for as much as $3bn.

You may also be interested in...



Apotex Mystery: Why Has Accord BioPharma Taken Its Place In US Biosimilar Pegfilgrastim Litigation?

Court grants request to substitute Accord BioPharma for Apotex in Amgen infringement suit. Apotex says it has no plans to exit the biosimilar business.

Apotex Mystery: Why Has Accord BioPharma Taken Its Place In Pegfilgrastim Biosimilar Litigation?

Court grants request to substitute Accord BioPharma for Apotex in Amgen infringement suit. Apotex says it has no plans to exit the biosimilar business.

C$10mn offered for Apotex Sherman lead

A reward of up to C$10 million (US$7.6 million) has been offered by the family of Apotex founder and chairman Barry Sherman “for information leading to the apprehension and prosecution of those responsible for the murders of Honey and Barry Sherman”.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB140236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel